Washington Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Washington Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4	Closed	-$427	–	868
2024 Q2	$427	Hold	4	–	–	﹤0.01%	856
2024 Q1	$482	Hold	4	–	–	﹤0.01%	833
2023 Q4	$492	Hold	4	–	–	﹤0.01%	813
2023 Q3	$518	Hold	4	–	–	﹤0.01%	876
2023 Q2	$496	Hold	4	–	–	﹤0.01%	885
2023 Q1	$585	Hold	4	–	–	﹤0.01%	916
2022 Q4	$637	Hold	4	–	–	﹤0.01%	930
2022 Q3	$1K	Hold	4	–	–	﹤0.01%	871
2022 Q2	$1K	Hold	4	–	–	﹤0.01%	875
2022 Q1	$1K	Hold	4	–	–	﹤0.01%	889
2021 Q4	$1K	Hold	4	–	–	﹤0.01%	898
2021 Q3	$1K	Hold	4	–	–	﹤0.01%	1017
2021 Q2	$1K	Buy	+4	New	+$693	﹤0.01%	1004
2020 Q3	–	Sell	-40	Closed	-$4K	–	1006
2020 Q2	$4K	Hold	40	–	–	﹤0.01%	721
2020 Q1	$4K	Buy	+40	New	+$5.17K	﹤0.01%	776
2018 Q3	–	Sell	-40	Closed	-$7K	–	525
2018 Q2	$7K	Buy	+40	New	+$6.54K	﹤0.01%	711

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Washington Trust's JAZZ Position: Q3 2024 in Review

Washington Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 4 shares — an estimated $427 sold.

Washington Trust first reported a position in JAZZ in Q2 2018 and held it in 16 quarters. The position peaked at $7K in Q2 2018. 478 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

Washington Trust reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Washington Trust sold 4 Jazz Pharmaceuticals shares in Q3 2024, an estimated $427.
Washington Trust first reported a position in Jazz Pharmaceuticals in Q2 2018 and held it in 16 quarters.
Washington Trust's Jazz Pharmaceuticals position peaked at $7K in Q2 2018.
478 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Washington Trust's 13F filing for Q3 2024, filed 25 Oct 2024.